|
64 Companies |
|
72 Products |
|
72 Products |
|
70 Mechanisms of Action |
|
1 Trial |
|
336 News |
|
| «1234567» |
- cixutumumab (IMC A12) / Eli Lilly
Trial completion: Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Mar 31, 2014
P2, N=114, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed
- Enrollment change, Surgery: Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 26, 2014
P2, N=1, Terminated, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed N=30 --> 1
- cixutumumab (IMC A12) / Eli Lilly
Enrollment change, Metastases: Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 18, 2014
P1, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=30 --> 1 N=30 --> 50
- everolimus / Generic mfg., sorafenib / Generic mfg.
Enrollment closed: SERIO: Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma (clinicaltrials.gov) - Mar 9, 2014
P2, N=37, Active, not recruiting, Sponsor: Italian Sarcoma Group
N=30 --> 50 Recruiting --> Active, not recruiting
- imetelstat (GRN163L) / Geron
Trial withdrawal: Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Mar 6, 2014
P2, N=0, Withdrawn, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Not yet recruiting --> Withdrawn
- imetelstat (GRN163L) / Geron
Enrollment change: Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Mar 6, 2014
P2, N=0, Withdrawn, Sponsor: Children's Oncology Group
Not yet recruiting --> Withdrawn N=110 --> 0
- | Neutrexin (trimetrexate) / Pfizer
Trial completion: Methotrexate, Trimetrexate Glucuronate, and Leucovorin in Treating Patients With Refractory or Recurrent Osteosarcoma (clinicaltrials.gov) - Feb 22, 2014
P1, N=18, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
N=110 --> 0 Recruiting --> Completed
- | oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Trial completion: Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas (clinicaltrials.gov) - Feb 22, 2014
P1, N=24, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed No longer recruiting --> Completed
- | tanespimycin (BMS-722782) / BMS
Trial completion: Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=70, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Active, not recruiting --> Completed
- | oxaliplatin / Generic mfg.
Trial completion: Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment (clinicaltrials.gov) - Feb 22, 2014
P2, N=180, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | temozolomide / Generic mfg., erlotinib / Generic mfg.
Trial completion: Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=95, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Trial completion: Alanosine in Treating Patients With Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
No longer recruiting --> Completed Active, not recruiting --> Completed
- | imatinib / Generic mfg.
Trial completion: Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor (clinicaltrials.gov) - Feb 22, 2014
P2, N=40, Completed, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | thalidomide / Generic mfg., docetaxel / Generic mfg.
Trial completion, Metastases: Thalidomide and Docetaxel in Treating Patients With Advanced Cancer (clinicaltrials.gov) - Feb 22, 2014
P1, N=26, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Diagnostic Study of Tumor Characteristics in Patients With Ewing's Sarcoma (clinicaltrials.gov) - Feb 22, 2014
P=N/A, N=637, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Marqibo (vincristine liposomal) / Servier, Aurobindo
Trial completion: Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies (clinicaltrials.gov) - Feb 22, 2014
P2, N=29, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Terminated --> Completed
- | ABT-751 / AbbVie, Eisai
Trial completion: ABT-751 in Treating Young Patients With Refractory Solid Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=90, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Terminated --> Completed Active, not recruiting --> Completed
- | imatinib / Generic mfg.
Trial completion, Metastases: Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, patupilone (EPO 906) / Novartis
Trial completion: Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy (clinicaltrials.gov) - Feb 22, 2014
P1, N=30, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
No longer recruiting --> Completed Recruiting --> Completed
- | bortezomib / Generic mfg.
Trial completion, Metastases: Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Completed Active, not recruiting --> Completed
- | Herceptin (trastuzumab) / Roche
Trial completion, Metastases: Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma (clinicaltrials.gov) - Feb 22, 2014
P2, N=80, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion, Epigenetic controller, Metastases: MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma (clinicaltrials.gov) - Feb 19, 2014
P1, N=75, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: COG-AEWS0031: Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor (clinicaltrials.gov) - Feb 19, 2014
P3, N=587, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Metastases: Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Ewing's Sarcoma or Rhabdomyosarcoma That Has Spread to the Bone (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=0, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Trial completion, Metastases: Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
No longer recruiting --> Completed Active, not recruiting --> Completed
- | tanespimycin (BMS-722782) / BMS
Trial completion, Metastases: 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma (clinicaltrials.gov) - Feb 19, 2014
P1, N=60, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Not yet recruiting --> Completed
- | irinotecan / Generic mfg.
Trial completion: Irinotecan in Treating Children With Refractory Solid Tumors (clinicaltrials.gov) - Feb 19, 2014
P2, N=181, Completed, Sponsor: Children's Oncology Group
Not yet recruiting --> Completed No longer recruiting --> Completed
- | Trial completion: Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
No longer recruiting --> Completed Not yet recruiting --> Completed
- | Trial completion, Surgery: Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Eastern Cooperative Oncology Group
Not yet recruiting --> Completed No longer recruiting --> Completed
- | Trial completion: Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating Patients With Ewing's Sarcoma, Peripheral Primitive Neuroectodermal Tumor, or Rhabdomyosarcoma (clinicaltrials.gov) - Feb 19, 2014
P1, N=16, Completed, Sponsor: Fred Hutchinson Cancer Research Center
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=24, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Suspended --> Completed
- | Neutrexin (trimetrexate) / Pfizer
Trial completion: Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia, Osteosarcoma, or Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 19, 2014
P2, N=25, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Suspended --> Completed Active, not recruiting --> Completed
- | Trial completion: Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | peripheral blood stem cell transplantation / National Cancer Institute
Trial completion, Metastases: A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas (clinicaltrials.gov) - Feb 19, 2014
P2, N=42, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed No longer recruiting --> Completed
- | plerixafor / Generic mfg.
Trial initiation date: A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone (clinicaltrials.gov) - Feb 18, 2014
P1/2, N=46, Recruiting, Sponsor: Genzyme, a Sanofi Company
No longer recruiting --> Completed Initiation date: Feb 2011 --> Feb 2014
- | plerixafor / Generic mfg.
Enrollment change: A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone (clinicaltrials.gov) - Feb 18, 2014
P1/2, N=46, Recruiting, Sponsor: Genzyme, a Sanofi Company
Initiation date: Feb 2011 --> Feb 2014 N=67 --> 46
- | plerixafor / Generic mfg.
Enrollment open: A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone (clinicaltrials.gov) - Feb 18, 2014
P1/2, N=46, Recruiting, Sponsor: Genzyme, a Sanofi Company
N=67 --> 46 Active, not recruiting --> Recruiting
- sorafenib / Generic mfg.
Enrollment change: Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07) (clinicaltrials.gov) - Feb 16, 2014
P2, N=15, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Recruiting N=24 --> 15
- Mepact (mifamurtide) / Takeda
Enrollment change: Surveillance Study of Patients With Newly Diagnosed Osteosarcoma (clinicaltrials.gov) - Jan 30, 2014
P=N/A, N=25, Active, not recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
N=24 --> 15 N=300 --> 25
- Mepact (mifamurtide) / Takeda
Enrollment closed: Surveillance Study of Patients With Newly Diagnosed Osteosarcoma (clinicaltrials.gov) - Jan 30, 2014
P=N/A, N=25, Active, not recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
N=300 --> 25 Recruiting --> Active, not recruiting
- Trial termination: Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer (clinicaltrials.gov) - Jan 30, 2014
P3, N=22, Terminated, Sponsor: University of South Florida
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; The study was terminated due to slow accrual.
- Enrollment change: Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer (clinicaltrials.gov) - Jan 30, 2014
P3, N=22, Terminated, Sponsor: University of South Florida
Active, not recruiting --> Terminated; The study was terminated due to slow accrual. N=178 --> 22
- Enrollment closed, Surgery, MRI: 18F-FLT Positron Emission Tomography and Diffusion-Weighted Magnetic Resonance Imaging in Planning Surgery and Radiation Therapy and Measuring Response in Patients With Newly Diagnosed Ewing Sarcoma (clinicaltrials.gov) - Jan 21, 2014
P=N/A, N=9, Active, not recruiting, Sponsor: Mayo Clinic
N=178 --> 22 Recruiting --> Active, not recruiting
- | Enrollment closed, Metastases: Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma (clinicaltrials.gov) - Jan 9, 2014
P2, N=20, Active, not recruiting, Sponsor: Stanford University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Enrollment closed, Combination therapy: Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma (clinicaltrials.gov) - Jan 5, 2014
P2, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Suspended --> Active, not recruiting
- methotrexate IV / Generic mfg.
New P2 trial, Adverse events: Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays? (clinicaltrials.gov) - Dec 25, 2013
P2, N=38, Recruiting, Sponsor: University College, London
- imetelstat (GRN163L) / Geron
New P2 trial: Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Dec 11, 2013
P2, N=0, Withdrawn, Sponsor: Children's Oncology Group
- Trial termination: Sodium Fluoride PET/CT for the Evaluation of Skeletal Cancer (clinicaltrials.gov) - Dec 9, 2013
P=N/A, N=2, Terminated, Sponsor: Stanford University
Suspended --> Active, not recruiting Recruiting --> Terminated; Low accrual and no funding
- Enrollment change: Sodium Fluoride PET/CT for the Evaluation of Skeletal Cancer (clinicaltrials.gov) - Dec 9, 2013
P=N/A, N=2, Terminated, Sponsor: Stanford University
Recruiting --> Terminated; Low accrual and no funding N=20 --> 2